-
公开(公告)号:US20080242653A1
公开(公告)日:2008-10-02
申请号:US11956816
申请日:2007-12-14
申请人: Huaqing Liu , Lawrence A. Black , Youssef L. Bennani , Marlon D. Cowart , Zhenping Tian , Paul J. Brackemeyer
发明人: Huaqing Liu , Lawrence A. Black , Youssef L. Bennani , Marlon D. Cowart , Zhenping Tian , Paul J. Brackemeyer
IPC分类号: A61K31/4025 , C07D207/04 , A61K31/40 , C07D403/02 , A61P25/18 , A61P25/28 , C07D205/02 , A61K31/506 , A61K31/501
CPC分类号: C07D401/12 , C07D207/06 , C07D207/08 , C07D207/12 , C07D213/82 , C07D295/14 , C07D295/155 , C07D401/10 , C07D403/10 , C07D403/12 , C07D417/10 , C07D417/12 , C07D495/04
摘要: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译: 式(I)的化合物,其中R 1,R 2,R 3,R 3a,R a, 在本说明书中定义的,可用于治疗由组胺-3受体配体预防或改善的病症或病症中的R 3,R 4,R 5和R 5 。 还公开了包含组胺-3受体配体的药物组合物,使用这些化合物和组合物的方法,以及制备式(I)范围内的化合物的方法。
-
公开(公告)号:US09108948B2
公开(公告)日:2015-08-18
申请号:US11956816
申请日:2007-12-14
申请人: Huaqing Liu , Lawrence A. Black , Youssef L. Bennani , Marlon D. Cowart , Zhenping Tian , Paul J. Brackemeyer
发明人: Huaqing Liu , Lawrence A. Black , Youssef L. Bennani , Marlon D. Cowart , Zhenping Tian , Paul J. Brackemeyer
IPC分类号: A61K31/50 , A61K31/501 , C07D401/02 , C07D237/04 , C07D401/12 , C07D207/06 , C07D207/08 , C07D207/12 , C07D213/82 , C07D295/14 , C07D295/155 , C07D401/10 , C07D403/10 , C07D403/12 , C07D417/10 , C07D417/12 , C07D495/04
CPC分类号: C07D401/12 , C07D207/06 , C07D207/08 , C07D207/12 , C07D213/82 , C07D295/14 , C07D295/155 , C07D401/10 , C07D403/10 , C07D403/12 , C07D417/10 , C07D417/12 , C07D495/04
摘要: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译: 其中R1,R2,R3,R3a,R3b,R4和R5在说明书中定义的式(I)化合物可用于治疗组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物,使用这些化合物和组合物的方法,以及制备式(I)范围内的化合物的方法。
-
公开(公告)号:US08829041B2
公开(公告)日:2014-09-09
申请号:US11766987
申请日:2007-06-22
IPC分类号: C07D207/09 , A61K31/409 , C07D207/06 , C07D417/10 , C07D401/10 , C07D495/04 , C07D403/10
CPC分类号: C07D207/06 , C07D401/10 , C07D403/10 , C07D417/10 , C07D495/04
摘要: Compounds of formula (I) are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).
摘要翻译: 式(I)化合物可用于治疗由组胺-3受体配体预防或改善的病症或病症。 还公开了包含组胺-3受体配体的药物组合物,使用这些化合物和组合物的方法,以及制备式(I)范围内的化合物的方法。
-
公开(公告)号:US08278313B2
公开(公告)日:2012-10-02
申请号:US12401385
申请日:2009-03-10
IPC分类号: A61K31/517
CPC分类号: C07D239/95 , C07D471/10 , C07D487/10
摘要: Macrocyclic Spiro pyrimidine compounds of formula (I): compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
摘要翻译: 本文描述了式(I)的大环螺嘧啶化合物:包含这些化合物的组合物,制备该化合物的方法,以及使用这些化合物和组合物治疗和预防疾病进展,病症和病症的方法。
-
公开(公告)号:US20090233904A1
公开(公告)日:2009-09-17
申请号:US12401385
申请日:2009-03-10
IPC分类号: A61K31/527 , C07D239/72 , A61K31/397 , A61P25/00 , A61P11/06
CPC分类号: C07D239/95 , C07D471/10 , C07D487/10
摘要: Macrocyclic spiro pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.
摘要翻译: 本文描述了大环螺嘧啶化合物,包含这些化合物的组合物,制备化合物的方法,以及使用这些化合物和组合物治疗和预防疾病,病症和病症进展的方法。
-
公开(公告)号:US08796297B2
公开(公告)日:2014-08-05
申请号:US12828104
申请日:2010-06-30
IPC分类号: A01N43/54 , A61K31/505
CPC分类号: A61K31/505 , A61K31/506 , A61K31/551 , C07D239/48 , C07D403/04 , C07D403/12 , C07D471/04 , C07D471/10 , C07D487/04
摘要: Compounds of the formula wherein R1 and R2 are as disclosed herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor full or partial agonists. Also disclosed are pharmaceutical compositions, methods for using such compounds and compositions, and processes for preparing the compounds.
摘要翻译: 下式的化合物其中R1和R2如本文所公开的,可用于治疗由组胺-3受体全部或部分激动剂预防或改善的病症或病症。 还公开了药物组合物,使用这些化合物和组合物的方法以及制备化合物的方法。
-
公开(公告)号:US08399468B2
公开(公告)日:2013-03-19
申请号:US12715660
申请日:2010-03-02
申请人: Marlon D. Cowart , Chen Zhao , Minghua Sun , Lawrence A. Black , Guo Zhu Zheng , Robert J. Gregg , Geoff G. Z. Zhang , Ahmad Y. Sheikh , Xiaochun Lou , Rodger F. Henry , David M. Barnes , Lawrence Kolaczkowski , Anthony R. Haight , Sou-Jen Chang , Steven J. Wittenberger , Michael G. Fickes
发明人: Marlon D. Cowart , Chen Zhao , Minghua Sun , Lawrence A. Black , Guo Zhu Zheng , Robert J. Gregg , Geoff G. Z. Zhang , Ahmad Y. Sheikh , Xiaochun Lou , Rodger F. Henry , David M. Barnes , Lawrence Kolaczkowski , Anthony R. Haight , Sou-Jen Chang , Steven J. Wittenberger , Michael G. Fickes
IPC分类号: A61K31/501 , C07D403/10
CPC分类号: C07D487/04
摘要: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
摘要翻译: 八氢吡咯并[3,4-b]吡咯衍生物可用于治疗组胺-3受体配体预防或改善的病症或病症。 八氢吡咯并[3,4-b]吡咯化合物,使用这些化合物的方法,制备它们的组合物和制备这些化合物的方法在本文中公开。
-
公开(公告)号:US07538138B2
公开(公告)日:2009-05-26
申请号:US11102415
申请日:2005-04-08
IPC分类号: C07D405/04 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , A61K31/343 , A61K31/44 , A61K31/47 , A61P25/00
CPC分类号: C07D231/12 , C07D233/56 , C07D249/08 , C07D307/79 , C07D307/81 , C07D333/54 , C07D405/04 , C07D405/06 , C07D407/04 , C07D409/04 , C07D409/10 , C07D413/04 , C07D417/04 , C07D491/08 , C07D491/10
摘要: Compounds of formula (I) or a pharmaceutically acceptable salts or prodrug thereof which are useful for the modulation of the histamine-3 receptors in mammals and which are useful for the treatment of disorders ameliorated by histamine-3 receptor ligands.
-
公开(公告)号:US07728031B2
公开(公告)日:2010-06-01
申请号:US11674518
申请日:2007-02-13
申请人: Marlon D. Cowart , Chen Zhao , Minghua Sun , Lawrence A. Black , Guo Zhu Zheng , Robert J. Gregg , Lawrence Kolaczkowski
发明人: Marlon D. Cowart , Chen Zhao , Minghua Sun , Lawrence A. Black , Guo Zhu Zheng , Robert J. Gregg , Lawrence Kolaczkowski
IPC分类号: A61K31/407 , A61K31/496 , C07D403/10 , C07D487/02
CPC分类号: C07D487/04
摘要: Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands, Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein.
摘要翻译: 八氢 - 吡咯并[3,4-b]吡咯衍生物可用于治疗组胺-3受体配体,八氢吡咯并[3,4-b]吡咯化合物,使用这些化合物的方法,组合物 制备这些化合物的方法和方法。
-
公开(公告)号:US20100331294A1
公开(公告)日:2010-12-30
申请号:US12828104
申请日:2010-06-30
IPC分类号: A61K31/506 , C07D239/48 , C07D403/12 , C07D403/04 , C07D471/10 , A61K31/505 , A61K31/551 , A61P25/06 , A61P29/00 , A61P3/04 , A61P9/00 , A61P1/00 , A61P1/16 , A61P25/00
CPC分类号: A61K31/505 , A61K31/506 , A61K31/551 , C07D239/48 , C07D403/04 , C07D403/12 , C07D471/04 , C07D471/10 , C07D487/04
摘要: Compounds of the formula wherein R1 and R2 are as disclosed herein, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor full or partial agonists. Also disclosed are pharmaceutical compositions, methods for using such compounds and compositions, and processes for preparing the compounds.
摘要翻译: 下式的化合物其中R1和R2如本文所公开的,可用于治疗由组胺3受体全部或部分激动剂预防或改善的病症或病症。 还公开了药物组合物,使用这些化合物和组合物的方法,以及制备化合物的方法。
-
-
-
-
-
-
-
-
-